… Efficacy and safety of Erlotinib versus chemotherapy in second-… of Erlotinib (E) versus
Docetaxel (D) as second- or third-line therapy in patients with advanced non-small cell lung cancer …

… of advanced non-small cell lung cancer (NSCLC) patients to receive third-line therapy. No
… This study respectively explores the efficacy and safety of single chemotherapy, epidermal …

… 比较埃克替尼作为晚期非小细胞肺癌（non-small cell lung cancer, NSCLC）二线治疗药物与…
This study compared the efficacy and safety of icotinib with standard second-line chemotherapy …

… treatment of non-small cell lung cancer (NSCLC). However, the role of pemetrexed therapy in
the third-line and beyond treatment of … the efficacy and safety of pemetrexed in the third-line …

… 小细胞肺癌(non-small cell lung cancer, NSCLC) 患者… Efficacy and safety of gefitinib as
thirdline treatment in NSCLC patients with activating EGFR mutations treated with first-line gefitinib …

… - and third-line therapy in patients with advanced non-small cell … the efficacy and safety of
EGFRTKI as first-line therapy. … 非替尼（gefitinib, Iressa）及厄洛替尼（erlotinib, Tarceva）的问世为…

… with locally advanced or metastatic non-small cell lung cancer (… efficacy and safety of
combined chemotherapy of vinorelbine and ifosfamide as third-line therapy or beyond for advanced …

… efficacy and survival of Icotinib hydrochloride for patients with advanced non-small cell lung
cancer … There was no statistical difference in RR and PFS between those age < 65 and ≥65 …